HRV Pharma has unveiled RIKO, a self-learning intelligent pharmaceutical operating system developed using the company's proprietary operational data, marking what it describes as a new approach to AI-driven decision-making across the pharmaceutical value chain.

Unlike conventional enterprise AI systems trained primarily on public data, RIKO™ has been built on millions of proprietary pharmaceutical decisions accumulated over seven years through HRV Pharma's network of more than 50 US FDA- and EU-GMP-certified manufacturing partners and customers across 55 countries.

The platform employs ten federated reasoning models that continuously retrain using a shared contextual architecture, enabling it to analyse chemistry risks, regulatory history, supplier performance, manufacturing capabilities and commercial opportunities simultaneously before key sourcing and licensing decisions are made.

According to the company, RIKO has already demonstrated measurable operational gains. The platform achieves 94% predictive accuracy in identifying potential nitrosamine-related risk patterns during early assessments, allowing technical teams to investigate issues before conventional review processes detect them.

The AI system has also reduced supplier qualification timelines by 85%, shortening a process that traditionally took four to eight weeks while retaining human oversight for final qualification decisions. In addition, it automatically screens all inbound commercial enquiries, completing opportunity scoring, supplier matching and commercial prioritisation in under two seconds.

HRV Pharma said the platform is designed to shift the pharmaceutical industry's focus from manufacturing scale to institutional intelligence by enabling proactive risk identification across quality, compliance, supply chain and commercial operations.

"We didn't begin by asking how AI could fit into our business. We started by asking why the same preventable problems continue to surface years after critical manufacturing and sourcing decisions have already been made. That question became the foundation of RIKO™," said Hari Kiran Chereddi, Founder, Managing Director and Chief Executive Officer, HRV Pharma.

Sowjanya Varma, Chief Information Officer, HRV Pharma, said, “We didn't build RIKO simply to automate work. We built it to compound judgment. Our objective has always been to identify risk beforehand—not after a quality failure, regulatory finding or product recall.”